Viking Global Investors Lp - Net Worth and Insider Trading
Viking Global Investors Lp Net Worth
The estimated net worth of Viking Global Investors Lp is at least $3.6 Billion dollars as of 2023-09-24. Viking Global Investors Lp is the 10% Owner of Myovant Sciences Ltd and owns about 40,765,599 shares of Myovant Sciences Ltd (MYOV) stock worth over $1.1 Billion. Viking Global Investors Lp is the 10% Owner of Roivant Sciences Ltd and owns about 75,238,700 shares of Roivant Sciences Ltd (ROIV) stock worth over $777 Million. Viking Global Investors Lp is also the 10% Owner of BridgeBio Pharma Inc and owns about 25,120,991 shares of BridgeBio Pharma Inc (BBIO) stock worth over $685 Million. Besides these, Viking Global Investors Lp also holds Urovant Sciences Ltd (UROV) , Adaptive Biotechnologies Corp (ADPT) , Inhibrx Inc (INBX) , Zentalis Pharmaceuticals Inc (ZNTL) , FIGS Inc (FIGS) , 4D Molecular Therapeutics Inc (FDMT) , RayzeBio inc (RYZB) , Amylyx Pharmaceuticals Inc (AMLX) , Rallybio Corp (RLYB) , Frazier Lifesciences Acquisition Corp (FLAC) , PROCEPT BioRobotics Corp (PRCT) , Sio Gene Therapies Inc (SIOX) . Details can be seen in Viking Global Investors Lp's Latest Holdings Summary section.
Transaction Summary of Viking Global Investors Lp
Viking Global Investors Lp Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Viking Global Investors Lp owns 21 companies in total, including Inhibrx Inc (INBX) , APi Group Corp (APG) , and Zentalis Pharmaceuticals Inc (ZNTL) among others .
Click here to see the complete history of Viking Global Investors Lp’s form 4 insider trades.
Insider Ownership Summary of Viking Global Investors Lp
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
INBX | Inhibrx Inc | 2023-08-28 | 10 percent owner |
APG | APi Group Corp | 2020-04-28 | 10 percent owner |
ZNTL | Zentalis Pharmaceuticals Inc | 2020-04-03 | 10 percent owner |
ADPT | Adaptive Biotechnologies Corp | 2019-06-26 | 10 percent owner |
ABUS | Arbutus Biopharma Corp | 2016-07-08 | 10 percent owner |
SIOX | Sio Gene Therapies Inc | 2016-07-08 | 10 percent owner |
MYOV | Myovant Sciences Ltd | 2016-10-26 | 10 percent owner |
UROV | Urovant Sciences Ltd | 2019-07-10 | other: Former 10% Owner |
BBIO | BridgeBio Pharma Inc | 2019-06-27 | 10 percent owner |
FDC | First Data Corp | 2016-04-13 | 10 percent owner |
EDIT | Editas Medicine Inc | 2016-02-02 | 10 percent owner |
W | Wayfair Inc | 2014-10-01 | 10 percent owner |
PRCT | PROCEPT BioRobotics Corp | 2022-03-18 | 10 percent owner |
ROIV | Roivant Sciences Ltd | 2021-10-01 | 10 percent owner |
FDMT | 4D Molecular Therapeutics Inc | 2023-05-09 | 10 percent owner |
AMLX | Amylyx Pharmaceuticals Inc | 2022-01-06 | 10 percent owner |
RLYB | Rallybio Corp | 2022-11-15 | 10 percent owner |
DNA | Ginkgo Bioworks Holdings Inc | 2022-03-02 | 10 percent owner |
FIGS | FIGS Inc | 2021-05-26 | 10 percent owner |
FLAC | Frazier Lifesciences Acquisition Corp | 2022-11-01 | 10 percent owner |
FLACU | Frazier Lifesciences Acquisition Corp | 2022-11-01 | 10 percent owner |
Viking Global Investors Lp Latest Holdings Summary
Viking Global Investors Lp currently owns a total of 15 stocks. Among these stocks, Viking Global Investors Lp owns 40,765,599 shares of Myovant Sciences Ltd (MYOV) as of June 4, 2019, with a value of $1.1 Billion and a weighting of 30.78%. Viking Global Investors Lp owns 75,238,700 shares of Roivant Sciences Ltd (ROIV) as of June 22, 2023, with a value of $777 Million and a weighting of 21.75%. Viking Global Investors Lp also owns 25,120,991 shares of BridgeBio Pharma Inc (BBIO) as of July 18, 2023, with a value of $685 Million and a weighting of 19.17%. The other 12 stocks Urovant Sciences Ltd (UROV) , Adaptive Biotechnologies Corp (ADPT) , Inhibrx Inc (INBX) , Zentalis Pharmaceuticals Inc (ZNTL) , FIGS Inc (FIGS) , 4D Molecular Therapeutics Inc (FDMT) , RayzeBio inc (RYZB) , Amylyx Pharmaceuticals Inc (AMLX) , Rallybio Corp (RLYB) , Frazier Lifesciences Acquisition Corp (FLAC) , PROCEPT BioRobotics Corp (PRCT) , Sio Gene Therapies Inc (SIOX) have a combined weighting of 28.29% among all his current holdings.
Latest Holdings of Viking Global Investors Lp
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
MYOV | Myovant Sciences Ltd | 2019-06-04 | 40,765,599 | 26.98 | 1,099,855,861 |
ROIV | Roivant Sciences Ltd | 2023-06-22 | 75,238,700 | 10.33 | 777,215,771 |
BBIO | BridgeBio Pharma Inc | 2023-07-18 | 25,120,991 | 27.27 | 685,049,425 |
UROV | Urovant Sciences Ltd | 2019-06-19 | 22,860,013 | 16.24 | 371,246,611 |
ADPT | Adaptive Biotechnologies Corp | 2020-12-14 | 29,993,708 | 5.07 | 152,068,100 |
INBX | Inhibrx Inc | 2023-08-28 | 7,150,826 | 19.48 | 139,298,090 |
ZNTL | Zentalis Pharmaceuticals Inc | 2020-12-01 | 3,943,284 | 21.27 | 83,873,651 |
FIGS | FIGS Inc | 2021-09-03 | 14,742,689 | 5.58 | 82,264,205 |
FDMT | 4D Molecular Therapeutics Inc | 2023-05-09 | 4,787,914 | 13.91 | 66,599,884 |
RYZB | RayzeBio inc | 2023-09-19 | 1,743,556 | 19.62 | 34,208,569 |
AMLX | Amylyx Pharmaceuticals Inc | 2022-09-09 | 1,850,940 | 18.48 | 34,205,371 |
RLYB | Rallybio Corp | 2021-07-29 | 4,194,777 | 4.86 | 20,386,616 |
FLAC | Frazier Lifesciences Acquisition Corp | 2022-11-02 | 1,211,582 | 9.87 | 11,958,314 |
PRCT | PROCEPT BioRobotics Corp | 2022-03-18 | 298,205 | 32.24 | 9,614,129 |
SIOX | Sio Gene Therapies Inc | 2019-03-18 | 13,244,048 | 0.38 | 4,966,518 |
Holding Weightings of Viking Global Investors Lp
Viking Global Investors Lp Form 4 Trading Tracker
According to the SEC Form 4 filings, Viking Global Investors Lp has made a total of 1 transactions in Myovant Sciences Ltd (MYOV) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Myovant Sciences Ltd is the acquisition of 2,424,242 shares on June 4, 2019, which cost Viking Global Investors Lp around $20 Million.
According to the SEC Form 4 filings, Viking Global Investors Lp has made a total of 1 transactions in Roivant Sciences Ltd (ROIV) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Roivant Sciences Ltd is the sale of 13,000,000 shares on June 22, 2023, which brought Viking Global Investors Lp around $129 Million.
According to the SEC Form 4 filings, Viking Global Investors Lp has made a total of 2 transactions in BridgeBio Pharma Inc (BBIO) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in BridgeBio Pharma Inc is the sale of 1,500,000 shares on July 18, 2023, which brought Viking Global Investors Lp around $53 Million.
More details on Viking Global Investors Lp's insider transactions can be found in the Insider Trading History of Viking Global Investors Lp table.Insider Trading History of Viking Global Investors Lp
- 1
Viking Global Investors Lp Trading Performance
GuruFocus tracks the stock performance after each of Viking Global Investors Lp's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Viking Global Investors Lp is 5.36%. GuruFocus also compares Viking Global Investors Lp's trading performance to market benchmark return within the same time period. The performance of stocks bought by Viking Global Investors Lp within 3 months outperforms 14 times out of 25 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Viking Global Investors Lp's insider trading performs compared to the benchmark.
Performance of Viking Global Investors Lp
Average Relative Return
15.16%
Outperforming Transactions
74%
1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
---|---|---|---|---|---|---|
Relative Return(%) | 3.49 | 5.36 | 19.01 | 15.16 | -7.5 | -22.95 |
Relative Return to S&P 500(%) | 1.13 | 1.41 | 10.52 | 6.1 | -19.65 | -36.4 |
Viking Global Investors Lp Ownership Network
Ownership Network List of Viking Global Investors Lp
Ownership Network Relation of Viking Global Investors Lp
Viking Global Investors Lp Owned Company Details

What does Inhibrx Inc do?
Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.
Who are the key executives at Inhibrx Inc?
Viking Global Investors Lp is the 10 percent owner of Inhibrx Inc. Other key executives at Inhibrx Inc include 10 percent owner David C. Ott , 10 percent owner Viking Global Opportunities Parent Gp Llc , and 10 percent owner Rose Sharon Shabet .
Inhibrx Inc (INBX) Insider Trades Summary
Over the past 18 months, Viking Global Investors Lp made 2 insider transaction in Inhibrx Inc (INBX) with a net purchase of 1,844,960. Other recent insider transactions involving Inhibrx Inc (INBX) include a net sale of 320,400 shares made by Brendan P. Eckelman , a net sale of 104,060 shares made by Mark Lappe , and a net sale of 38,000 shares made by Jon Faiz Kayyem .
In summary, during the past 3 months, insiders sold 0 shares of Inhibrx Inc (INBX) in total and bought 511,627 shares, with a net purchase of 511,627 shares. During the past 18 months, 462,460 shares of Inhibrx Inc (INBX) were sold and 1,844,960 shares were bought by its insiders, resulting in a net purchase of 1,382,500 shares.
Inhibrx Inc (INBX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Inhibrx Inc Insider Transactions
Viking Global Investors Lp Mailing Address
Above is the net worth, insider trading, and ownership report for Viking Global Investors Lp. You might contact Viking Global Investors Lp via mailing address: 55 Railroad Avenue, Greenwich Ct 06830.